Transcriptional co-activators YAP/TAZ: Potential therapeutic targets for metastatic breast cancer - 19/12/20
pages | 11 |
Iconographies | 5 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | The transcriptional co-activator YAP/TAZ is the key target to mediate breast cancer metastasis. |
• | YAP/TAZ mediates metastasis through cytoskeleton maintenance, vascular adhesion, EMT, cell stemness maintenance. |
• | •Different post-translational modifications of YAP/TAZ have different effects on metastatic breast cancer. |
• | •Targeting YAP/TAZ post-translational modification provides a new strategy for the treatment of metastatic breast cancer. |
• | •YAP/TAZ can interact with various pathways (PI3K-mTOR, ERBB4, ABL kinase, Amot, Wnt/β-catenin pathway). |
Abstract |
Breast cancer is the most commonly diagnosed cancer among women. Although routine and targeted therapies have improved the survival rate, there are still considerable challenges in the treatment of breast cancer. Metastasis is the leading cause of death in patients diagnosed with breast cancer. Yes-associated protein (YAP) and/or PDZ binding motif (TAZ) are usually abnormally activated in breast cancer leading to a variety of effects on tumour promotion, such as epithelial-mesenchymal transition, cancer stem cell production and drug-resistance. The abnormal activation of YAP/TAZ can affect metastasis-related processes and promote cancer progression and metastasis by interacting with some metastasis-related factors and pathways. In this article, we summarise the evidence that YAP/TAZ regulates breast cancer metastasis, its post-translational modification mechanisms, and the latest advances in the treatment of YAP/TAZ-related breast cancer metastasis, besides providing a new strategy of YAP/TAZ-based treatment of human breast cancer.
Le texte complet de cet article est disponible en PDF.Abbreviations : YAP, TAZ, SH3, TBD, TAD, WWTR1, MST1/2, LATS1/2, EMT, ECM, FAK, SnoN, BCSCs, SRF, CYR61, CTGF, GDF15, DDIT4, Trail, PTMs, SKP2, HAUSP, OTUB2, LAP, HBP, OGT, mTOR, ICD, NRG1, Amot, AmotL1, DVL, WBP2, TNBC, REV, NSAID
Keywords : YAP/TAZ, Hippo pathway, Post-translational modification, Metastatic breast cancer, Targeted therapy
Plan
Vol 133
Article 110956- janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?